Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Jun 9, 2017
Insider Transaction Report
Form 4
DOUMANI ROY
Director
Transactions
- Sale
Common Stock
2017-06-07$84.46/sh−10,000$844,621→ 155,017 total - Sale
Common Stock
2017-06-08$84.53/sh−5,000$422,634→ 150,017 total
Holdings
- 25,065(indirect: By Spouse)
Common Stock
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.265 to $85.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.